NCT04527523

Brief Summary

This study aims to evaluate and compare incidence of post-operative cystoid macular edema (CME) after Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet's Stripping Automated endothelial Keratoplasty (DSEK) and Descemet Stripping Only (DSO).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 26, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

November 21, 2020

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 24, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 24, 2022

Completed
Last Updated

January 13, 2023

Status Verified

January 1, 2023

Enrollment Period

1.8 years

First QC Date

August 21, 2020

Last Update Submit

January 11, 2023

Conditions

Keywords

endothelial transplantsendothelial dysfunction

Outcome Measures

Primary Outcomes (4)

  • Incidence of Post-Op CME

    The frequency (number of Subjects) of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO.

    6 weeks post-operative

  • Incidence of Post-Op CME

    The frequency (number of Subjects) of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO.

    3 months post-operative

  • Severity of Post-Op CME

    The severity of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO that experience Cystoid Macular Edema after surgery - measured by net change of Central Foveal Thickness on Optical Coherence Tomography (OCT- is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media, e.g., biological tissue)

    6 weeks post-operative

  • Severity of Post-Op CME

    The severity of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO that experience Cystoid Macular Edema after surgery - measured by net change of Central Foveal Thickness on Optical Coherence Tomography (OCT- is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media, e.g., biological tissue)

    3 months post-operative

Secondary Outcomes (4)

  • Graft Detachment

    6 weeks and 3 months post-operative

  • Re-bubbling Procedure

    6 weeks and 3 months post-operative

  • Infection

    6 weeks and 3 month post-operative

  • Final Visual Acuity

    3 months post-operative

Study Arms (1)

Endothelial Dysfunction Cohort

All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.

Diagnostic Test: Optical Coherence Tomography

Interventions

OCT is an imaging method that uses light waves to create images of the retina.

Also known as: OCT
Endothelial Dysfunction Cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with endothelial dysfunction that require treatment, and are being evaluated for Descemet Stripping Only (DSO), Descemet Membrane Endothelial Keratoplasty (DMEK) or Descemet's Stripping Automated Endothelial Keratoplasty (DSEK)

You may qualify if:

  • Any patient that is undergoing DSO or endothelial corneal transplantation vis DMEK or DSEK

You may not qualify if:

  • Patients that do not have an optical coherence tomography measurement pre- operatively
  • Patients that don't have an optical coherence tomography measurement post- operatively
  • Patients with a previous history of uncontrolled macular edema

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location

Related Publications (4)

  • Inoda S, Hayashi T, Takahashi H, Oyakawa I, Yokogawa H, Kobayashi A, Kato N, Kawashima H. Risk Factors for Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea. 2019 Jul;38(7):820-824. doi: 10.1097/ICO.0000000000001950.

    PMID: 30973407BACKGROUND
  • Kocaba V, Mouchel R, Fleury J, Marty AS, Janin-Manificat H, Maucort-Boulch D, Burillon C. Incidence of Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea. 2018 Mar;37(3):277-282. doi: 10.1097/ICO.0000000000001501.

    PMID: 29298168BACKGROUND
  • Arbelaez JG, Price MO, Price FW Jr. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea. 2014 Dec;33(12):1295-9. doi: 10.1097/ICO.0000000000000270.

    PMID: 25299425BACKGROUND
  • Koenig SB. Planned Descemetorhexis Without Endothelial Keratoplasty in Eyes With Fuchs Corneal Endothelial Dystrophy. Cornea. 2015 Sep;34(9):1149-51. doi: 10.1097/ICO.0000000000000531.

    PMID: 26186374BACKGROUND

MeSH Terms

Conditions

Macular EdemaFuchs' Endothelial Dystrophy

Interventions

Tomography, Optical Coherence

Condition Hierarchy (Ancestors)

Macular DegenerationRetinal DegenerationRetinal DiseasesEye DiseasesCorneal Dystrophies, HereditaryCorneal DiseasesEye Diseases, HereditaryGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Tomography, OpticalOptical ImagingDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisTomographyInvestigative Techniques

Study Officials

  • Matthew Giegengack

    Wake Forest Health Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2020

First Posted

August 26, 2020

Study Start

November 21, 2020

Primary Completion

August 24, 2022

Study Completion

August 24, 2022

Last Updated

January 13, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

IPD will not be shared. Final, overall results will be reported for each outcome.

Locations